Structure Therapeutics (NASDAQ:GPCR) Stock Rating Reaffirmed by Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a research note issued to investors on Thursday morning, Benzinga reports. The brokerage currently has a $65.00 target price on the stock.

GPCR has been the subject of a number of other reports. JPMorgan Chase & Co. began coverage on shares of Structure Therapeutics in a research note on Tuesday, May 21st. They set an overweight rating and a $65.00 price objective for the company. JMP Securities reduced their price objective on shares of Structure Therapeutics from $91.00 to $86.00 and set a market outperform rating for the company in a research note on Friday, August 9th. Finally, BMO Capital Markets increased their price objective on shares of Structure Therapeutics from $83.00 to $100.00 and gave the stock an outperform rating in a research note on Friday, June 7th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics has a consensus rating of Buy and an average target price of $84.63.

Structure Therapeutics Trading Up 1.7 %

Shares of NASDAQ GPCR opened at $37.12 on Thursday. The firm has a market cap of $1.73 billion, a PE ratio of -48.21 and a beta of -3.52. Structure Therapeutics has a 1-year low of $25.57 and a 1-year high of $75.02. The company has a fifty day moving average price of $40.24 and a 200 day moving average price of $40.50.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. Equities research analysts forecast that Structure Therapeutics will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Sandia Investment Management LP bought a new stake in shares of Structure Therapeutics in the 2nd quarter valued at about $39,000. Quarry LP bought a new stake in shares of Structure Therapeutics in the 2nd quarter valued at about $79,000. Sectoral Asset Management Inc. bought a new stake in shares of Structure Therapeutics in the 4th quarter valued at about $139,000. ADAR1 Capital Management LLC bought a new stake in shares of Structure Therapeutics in the 4th quarter valued at about $163,000. Finally, Mather Group LLC. bought a new stake in shares of Structure Therapeutics in the 2nd quarter valued at about $214,000. 91.78% of the stock is owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.